Midweek Takeaway with James Short, CEO of Celadon Pharmaceuticals (AIM:CEL) #CEL

In this episode of The Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by James Short, CEO of Celadon Pharmaceuticals (AIM: CEL), to discuss the company’s major strategic update. Celadon has announced plans to delist from the AIM market and transition to a private limited company, subject to shareholder approval at the upcoming General Meeting on 28 July 2025. James explains the reasoning behind this bold move, its implications for investors and patients, and how the business will continue to evolve in the medical cannabis space as a privately held company.

Disclaimer & Declaration of Interest

This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.